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Abstract Lymphatic vessels have traditionally been regar-
ded as a rather inert drainage system, which just passively
transports fluids, leukocytes and antigen. However, it is
becoming increasingly clear that the lymphatic vasculature is
highly dynamic and plays a much more active role in
inflammatory and immune processes. Tissue inflammation
induces a rapid, stimulus-specific upregulation of chemokines
and adhesion molecules in lymphatic endothelial cells and a
proliferative expansion of the lymphatic network in the
inflamed tissue and in draining lymph nodes. Moreover,
increasing evidence suggests that inflammation-induced
changes in the lymphatic vasculature have a profound impact
on the course of inflammatory and immune responses, by
modulating fluid drainage, leukocyte migration or the removal
of inflammatory mediators from tissues. In this review we will
summarize and discuss current knowledge of the inflamma-
tory response of lymphatic endothelium and of inflammation-
induced lymphangiogenesis and the current perspective on the
overall functional significance of these processes.
Keywords Inflammation  Lymphatic endothelial
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Introduction
Lymphatic vessels (LVs) are present in most vascularized
tissues. By absorbing excess tissue fluid and returning it to
the blood vascular circulation, LVs essentially contribute to
tissue fluid homeostasis [1, 2]. Moreover, LVs transport
soluble antigen and leukocytes and therefore are important
for immune function [3]. Afferent LVs begin as blind-
ended capillaries, which give rise to collecting vessels that
eventually merge and connect with draining lymph nodes
(dLNs) (Fig. 1a). Initial lymphatic capillaries are com-
posed of oak-leaf shaped lymphatic endothelial cells
(LECs) that are connected by discontinuous, button-like
cell junctions [4]. This setup gives rise to characteristic
flaps, which represent the prime sites of leukocyte and fluid
entry into LVs [4, 5]. By contrast, collecting LVs are
ideally adapted for the transport of lymph; here, cuboidal
LECs are tightly connected by continuous, zipper-like cell
junctions. Moreover, collecting LVs contain valves and are
surrounded by a continuous basement membrane and a
smooth muscle cell layer [1].
Research of the last 15 years has revealed that the
lymphatic network in peripheral tissues and in LNs is
highly plastic and undergoes substantial changes under
pathologic conditions [1, 2]. For example, tissue inflam-
mation induces rapid, stimulus-specific changes in LEC
gene expression and a stimulus-specific expansion and
remodeling of the lymphatic network. In humans, inflam-
mation-induced lymphangiogenesis has been reported for
psoriasis [6], rheumatoid arthritis [7], inflammatory bowel
disease [8], atherosclerosis [9], chronic airway inflamma-
tion [10] as well as for transplant rejection [11, 12] and
lymphedema [13]. Furthermore, recent animal studies have
revealed that inflammation-induced lymphangiogenesis
directly impacts the course of inflammatory and immune
responses, by modulating fluid drainage, leukocyte migra-
tion or the removal of inflammatory mediators from tissues
[10, 14–19]. Increasing evidence also suggests that LVs
and LECs directly crosstalk with the immune system and
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are involved in antigen presentation and tolerance induc-
tion in LNs [20–22]. The latter processes have been the
focus of excellent recent reviews [23, 24] and therefore
will not be discussed in further detail.
In this review we will introduce the best characterized
mediators of inflammatory lymphangiogenesis and sum-
marize current knowledge about inflammation-induced
gene expression changes in LECs. Furthermore, we will
focus on the morphologic and structural changes of LVs in
inflamed tissues and in dLNs. Finally, we will summarize
how inflammation-induced lymphangiogenesis and lym-
phatic remodeling are thought to impact the inflammatory
process, by modulating leukocyte trafficking, fluid drainage
and chemokine levels in inflamed tissues.
Mediators of inflammation-induced lymphangiogenesis
The best-studied mediators of inflammation-induced lym-
phangiogenesis are vascular endothelial growth factor
(VEGF)-C and VEGF-A, which are produced by stromal
cells like keratinocytes or fibroblasts as well as by
leukocytes in inflamed tissues [1, 2, 25]. Particularly
macrophages are a major source of VEGF-A and VEGF-C
[26–28]. In various inflammatory models, depletion of
macrophages was shown to significantly reduce lymphan-
giogenesis [26–29]. Notably, macrophages may also
physically contribute to lymphangiogenesis by up-regulat-
ing lymphatic marker genes and incorporating into LVs
[11, 29]. Besides VEGF family members, also other leu-
kocyte-derived cytokines contribute to inflammation-
induced lymphangiogenesis (Table 1). For example, lym-
photoxin (LT)a and LTab2 have been implicated in
inflammatory lymphangiogenesis during infection or ter-
tiary lymphoid organ formation [30, 31]. Similarly, inter-
leukin 17 (IL-17) was shown to induce lymphangiogenesis
in a mouse model of ocular autoimmunity [32], whereas
IL-8 promoted LV regeneration and reduced post-surgical
lymphedema formation [33]. Interestingly, also some
inflammatory cytokines with anti-lymphangiogenic activity
have been identified (Table 1). For example, IFNc, a
mainly T cell-derived cytokine, reportedly inhibits LECs
in vitro and in vivo [34–36]. Moreover, inhibition of
transforming growth factor beta (TGFb) was shown to
Fig. 1 Inflammation-induced lymphangiogenesis in peripheral tis-
sues and in dLNs. a Anatomy of the lymphatic vasculature at steady
state: afferent LVs are composed of initial capillaries and collecting
vessels. The lymphatic network in LNs mainly comprises the
subcortical and medullary sinus. b During tissue inflammation,
lymphangiogenic growth factors, such as VEGF-C/D or VEGF-A, are
secreted by tissue-infiltrating leukocytes or by stromal cells. These
factors induce a proliferative growth of the lymphatic vasculature by
lymphatic sprouting or enlargement of preexisting vessels. At the
same time, lymphangiogenesis occurs in dLNs. LN lymphangiogen-
esis-inducing factors are either produced locally (e.g. VEGF-A
produced by B cells) or drained to the LN from the inflamed tissue.
Depending on the type of inflammatory response induced, LN
lymphangiogenesis may be counterbalanced by inhibitory factors (i.e.
IFNc produced by activated T cells)
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enhance lymphangiogenesis in thioglycollate-induced
peritonitis [37] and to induce lymphangiogenesis and
lymphatic drainage in a murine lymphedema model [38].
Overall, the balance of pro- and anti-lymphangiogenic
cytokine expression appears to determine the extent and
nature of inflammation-induced lymphangiogenesis. This
generates a very flexible system, in which tailored
lymphangiogenic responses are initiated, depending on the
type of inflammatory immune response elicited.
Inflammation-induced changes in LEC gene expression
In vitro many inflammatory mediators, such as growth
factors, cytokines or pathogen-derived molecules induce
LEC proliferation, migration or tube formation and there-
fore exert a pro-lymphangiogenic activity (Table 1). Con-
versely, other mediators appear to rather suppress these
processes or to mainly modulate the gene expression phe-
notype of LECs. For example, inflammatory cytokines such
as TNFa, IFNc, IL-1 induce no or little LEC proliferation
[35], but are strong inducers of inflammatory chemokines
and adhesion molecules like ICAM-1 and VCAM-1, which
participate in leukocyte trafficking [35, 39–41]. In fact,
leukocyte trafficking via afferent LVs is typically enhanced
in the context of inflammation [3, 42, 43].
Adhesion molecules
Inflammatory signals have been shown to modulate the
expression of ICAM-1 and VCAM-1 [39, 40], P-selectin
[40], E-selectin [39, 44], L1CAM [45], ALCAM [46] or
CAR [47] in LECs. While some of these molecules con-
tribute to lymphangiogenesis [46, 47], others mediate leu-
kocyte trafficking via afferent LVs [39, 45, 48]. Particularly
inflammation-induced ICAM-1 or VCAM-1 were shown to
be important for dendritic cell (DC) transmigration into [39,
48] and migration within LVs [49]. LVs in resting tissues
express very low levels of ICAM-1 and VCAM-1, but these
adhesion molecules are strongly upregulated in LECs dur-
ing tissue inflammation. This might explain why DC
migration in absence of inflammation occurs independently
of ICAM-1 or VCAM-1 binding integrins [50]. By contrast,
blockade of ICAM-1, VCAM-1 or of the DC-expressed
integrin LFA-1 significantly reduced DC migration to dLNs
in the context of skin inflammation [39, 48]. Interestingly,
interactions between LEC-expressed ICAM-1 and DC-
expressed Mac-1 (CD11b) occurring in the process of DC
migration to dLNs were also shown to modulate the mat-
uration state and function of DCs [51].
Chemokines
Various chemokines are upregulated in LECs in response
to inflammatory signals (Table 2). The chemokine with the
best documented role in leukocyte trafficking into LVs is
CCL21, which attracts CC-chemokine receptor 7 (CCR7)
expressing leukocytes, such as DCs or T cells [3]. Tissue
inflammation was shown to upregulate CCL21 protein
expression in vivo [40]. Moreover, TNFa, VEGF-C as well
as transmural flow were identified as inducers of CCL21
expression in LECs [42, 52, 53] (Table 2). Interestingly, a
substantial fraction of CCL21 is stored intra-cellularly in
vesicles of the Trans-Golgi Network [40, 54]. In vitro
treatment of LECs with TNFa was shown to induce rapid
secretion of CCL21 from its intracellular stores [55], but it
is still unclear how tissue inflammation affects CCL21
secretion in vivo. Interestingly, also neutrophil migration
via afferent LVs, which occurs during acute inflammation,
is mainly CCR7-dependent [56]. Similarly, CCR7 expres-
sion was shown to be the main determinant of regulatory
and effector T cell migration into LVs during acute
inflammation [3, 43]. However, the CCR7-dependence of T
cell migration into lymphatics appears to be less strong in
Table 1 Inflammatory mediators with documented pro- or anti-
lymphangiogenic activity
Mediator Lymphangiogenic
activity
In vitro (1)
In vivo (2)
References
VEGF-C ? 1 & 2 [72, 105]
VEGF-A ? 1 & 2 [72, 105]
LTa ? 2 [31]
LTab2 ? 1 & 2 [30, 106]
IL-17 ? 1 & 2 [32]
IL-8
(CXCL8)
? 1 & 2 [33, 107]
HGF ? 1 & 2 [108]
IL-3 ? 1 [66]
FGF-2
(bFGF)
? 1 & 2 [65]
LPS ? 1 & 2 [61, 66]
CXCL12 ? 1 & 2 [59]
S1P ? 1 & 2 [109]
TNFa - 1 [35]
IL-27 - 1 [60]
IFNa - 1 [34]
IFNc - 1 & 2 [34–36]
TGFb - 1 & 2 [37, 38]
CXCL10/11 - 1 [60]
Various inflammatory mediators have been shown to induce or inhibit
lymphangiogenesis in vitro or in vivo. Lymphangiogenic activity: (?)
pro-lymphangiogenic activity, (-) anti-lymphangiogenic activity.
In vitro/in vivo activity: (1) shown to modulate LEC in vitro prolif-
eration, migration, or tube formation, (2) shown to modulate lym-
phangiogenesis in vivo. HGF hepatocyte growth factor, S1P
sphingosine-1-phosphate
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the context of chronic inflammation [43], suggesting a role
for other inflammation-induced chemokines or other che-
motactic molecules under this condition.
Besides CCL21, various other chemokines are upregu-
lated in LECs in response to inflammatory signals
(Table 2), but thus far only two further chemokines have
been shown to support leukocyte migration into afferent
LVs. Inflammation-induced CXCL12 reportedly enhanced
the migration of CXCR4-expressing dermal DCs and
Langerhans cells to dLNs [57]. Moreover, LEC-expressed
CX3CL1 (fractalkine) was recently shown to support DC
transmigration across lymphatic endothelium and the
overall trafficking process from inflamed tissue to dLNs
[58]. On the other hand, experiments performed in
CCR7-/- mice revealed that DC migration to dLNs
remained strictly CCR7-dependent in the context of skin
inflammation [40]. Thus, although CCL21/CCR7 signaling
remains of key importance for DC migration during
inflammation, also other LEC-expressed chemokines con-
tribute to this process, possibly by affecting distinct steps in
the migration cascade.
In analogy to the role of chemokines in angiogenesis,
increasing evidence suggests that inflammation-induced
chemokines may be involved in the regulation of lym-
phangiogenesis. For example CXCL12 reportedly induces
lymphangiogenesis in vitro and in vivo [59]. Similarly,
CXCL8 (IL-8), which is upregulated in LECs in response
to various inflammatory stimuli, reportedly enhances
lymphangiogenesis [33, 41]. By contrast, inflammation-
induced CXCL10 and CXCL11 (Table 2) were shown to
exert anti-lymphangiogenic activity in vitro [60]. It has
also been suggested that the upregulation of chemokines
might serve to indirectly support lymphangiogenesis. In a
murine peritonitis model, inflammation-induced chemo-
kine expression in LECs was responsible for the attraction
and association of macrophages with LVs, what in turn
induced lymphangiogenesis by macrophage-derived
lymphangiogenic growth factors [61].
Stimulus-specific changes in LEC gene expression
Several studies have revealed that many changes in LEC
gene expression occur in a highly stimulus-specific manner
[35, 39–41, 62]. For example, performing gene expression
analyses of LECs isolated from inflamed or resting murine
Table 2 Inflammatory
mediators inducing chemokine
expression in LECs
Various inflammatory stimuli
have been shown to induce
chemokine expression in LECs
in vitro or in vivo. Chemokines
written in bold font: protein
expression reported.
Chemokines written in regular
font: mRNA expression
reported
MDP muramyl dipeptide, LTA
lipoteichoic acid, DNFB
dinitrofluorobenzene
Inflammatory 
stimulus 
Chemokines
induced Comment Ref. 
in vitro 
TLR ligands 
(TLR2/3/4/6/8/9) 
CCL5, 20, 21; 
CXCL8/9/10/11/12 
stimulus-specific 
responses [41] 
TLR ligands 
(TLR1/2/3/4/6/9) 
CCL2/5 
CXCL8
stimulus-specific 
responses [62] 
LPS CCL2/3/5/7/8/20 CXCL1/3/5/6/8 [44] 
LPS CCL2/5 CX3CL1 [61] 
TNFα
CCL2/5/20/21 
CXCL2/5 
CX3CL1 
[39 ] 
TNFα CCL21 [55] 
TNFα / IFNγ CCL2/7 CXCL5/9/10 [40] 
MDP / LTA CCL2/7 CXCL5 [40] 
Transmural flow CCL21 [53] 
VEGF-C CCL21 [52] 
in vivo
LPS injection CCL2 peritoneal inflammation [61] 
CHS response to 
DNFB CXCL12 skin inflammation [57] 
CHS response to 
oxazolone 
CCL2/7/8/21
CXCL1/5/9/10 skin inflammation [40] 
CFA injection CCL2/7/21CXCL5 skin inflammation [40] 
VEGF-C CCL21 Intradermal injection  [52] 
TNFα CCL21 Intradermal injection [42] 
Lymph flow CCL21 lymphedema or 
overhydration [53] 
Pancreatic islet 
inflammation 
CCL2, CCL21 
CXCL10 
mouse model of 
autoimmune 
diabetes 
[110] 
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ear skin we have recently observed that inflammation
elicited by a contact hypersensitivity (CHS) response to
oxazolone or by CFA injection induced a similar degree of
tissue swelling, but a differential upregulation of inflam-
matory chemokines (Table 2) and of adhesion molecules
(e.g. ICAM-1, P-selectin) [40]. Stimulus-specific upregu-
lation of chemokines and of ICAM-1 or VCAM-1 was also
observed in other studies when treating LECs in vitro with
different cytokines or with Toll-like receptor (TLR) ligands
[35, 39–41, 62]. It is likely that stimulus-specific upregu-
lation of trafficking molecules serves to fine-tune leukocyte
migration or other chemokine-induced responses in LECs
in the context of the ongoing immune response.
Inflammation also modulates the expression of lym-
phatic marker genes in a stimulus-specific manner. Various
stimuli reportedly induce down-regulation of the hyaluro-
nan receptor LYVE-1 in LECs [10, 40, 63]. The signifi-
cance of this down-regulation is presently unclear, but
recent findings suggest that loss of LYVE-1 may alter LEC
barrier function [64]. Interestingly, LYVE-1 was also
shown to bind and to enhance the activity of fibroblast
growth factor-2 (FGF2), an inflammation-induced factor
with reported lymphangiogenic activity [65]. Also the
transcription factor Prox-1 and its target gene VEGFR-3
were shown to be down-regulated in LECs in the context of
CHS-induced skin inflammation [15, 40]. By contrast,
Prox-1 and VEGFR-3 expression remained constant during
tissue inflammation induced by CFA injection [40],
whereas both genes were upregulated in LVs in a mouse
model of thioglycollate-induced peritonitis [66]. It is per-
ceivable that modulation of Prox-1 affects lymphatic dif-
ferentiation, whereas changes in VEGFR3 expression
likely affect LEC responsiveness towards inflammation-
induced VEGF-C.
Inflammation-induced changes in afferent LVs
Inflammation leads to a rapid dilation of LVs in tissues [1,
67, 68]. Additionally, the size of the lymphatic network
increases due to proliferative expansion [68–70]. This may
feature a proliferative enlargement of preexisting vessels
[67] or the sprouting of new LVs [27, 28, 66] (Fig. 1b).
Interestingly, the extent of lymphangiogenic sprouting
versus expansion of preexisting vessels appears to depend
on the lymphangiogenesis-inducing stimuli. VEGF-A was
shown to mainly induce LV enlargement [71, 72], whereas
VEGF-C induced sprouting lymphangiogenesis [72, 73].
Besides changing lymphatic morphology, persistent
inflammation may also alter the typical organization of
lymphatic cell junctions [4]. In a model of chronic airway
inflammation induced by infection with Mycoplasma pul-
monis, the characteristic button-like cell junctions were
replaced by continuous, zipper-like junctions [74]. The
functional significance of this conversion is not known, but
it is likely that these structural differences affect lymphatic
drainage or leukocyte migration.
Inflammation-induced changes in the lymphatic
network in dLNs
Inflammation-induced lymphangiogenesis does not only
affect the inflamed tissue but also extends to dLNs [36, 68–
70, 75] (Fig. 1b). In a mouse model of skin inflammation
induced by immunization with complete Freund’s adju-
vants (CFA), LN lymphangiogenesis was mainly driven by
VEGF-A secreted from LN-resident B cells. By contrast, in
a mouse model of chronic skin inflammation induced by a
CHS response to oxazolone, LN lymphangiogenesis was
shown to be mediated by VEGF-A that was drained to the
LN from its production site in the inflamed skin [68].
Different from nodal B cells, activated T cells appear to
have a negative impact on LN lymphangiogenesis. IFNc
secreted by activated T cells reportedly inhibits LN lym-
phangiogenesis and limits the size of the lymphatic net-
work in the LN T cell area in steady state and in
inflammation [36, 75]. Thus, it appears that depending on
the inflammatory stimulus and the type of immune
response induced, the pattern and extent of LN lymphan-
giogenesis may vary. As a further illustration of this
hypothesis; lipopolysaccharide (LPS) injection into the
skin was shown to promote LN lymphangiogenesis,
whereas injection of the T cell mitogen concanavalin-A did
not increase the lymphatic vasculature in the dLN,
although both agents accounted for potent inflammatory
reactions at the site of injection [36].
Intriguingly, experiments in mouse models of lymphe-
dema have revealed that lymphedema formation was
reduced and lymphatic regeneration and drainage were
enhanced in mice devoid of T cells [75] or upon depletion
of CD4? T cells [76]. The latter findings suggest that
T-cell-derived mediators might also negatively impact
lymphangiogenesis and LV function outside of the LN.
Regarding to functional significance of inflammation-
induced LN lymphangiogenesis, experimental evidence
suggests that this process serves to regulate leukocyte
migration to and from LNs. In the context of CFA-induced
inflammation, VEGFR-2- and VEGFR3-mediated blockade
of LN lymphangiogenesis was shown to reduce DC
migration to dLNs [69] as well as lymphocyte egress via
efferent lymphatics [70]. On the other hand, LECs in LNs
have been shown to present antigen to T cells and to par-
ticipate in tolerance induction [21, 22]. Thus, it is likely
that LN lymphangiogenesis directly modulates the induc-
tion of adaptive immunity in LNs [23, 24].
Angiogenesis (2014) 17:383–393 387
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Role of afferent LVs in modulating inflammatory
and immune responses
Several studies have shown that tissue inflammation not
only alters LV morphology but also changes lymphatic
function, for example the capacity of LVs to mediate leu-
kocyte migration or to drain tissue fluids [10, 14–19]. Such
changes in LV function profoundly impact the persistence
or resolution of tissue inflammation. In the following sec-
tions, the impact of alterations in LV immune and drainage
functions on the inflammatory response shall be discussed
in greater detail.
Leukocyte trafficking
Besides removing tissue fluids and inflammatory media-
tors, the lymphatic network is also thought to contribute to
the downregulation and resolution of inflammation by
facilitating tissue exit of leukocytes. For example, regula-
tory T cells have been identified as a major cell type
emigrating from inflamed skin to dLNs, where they are
thought to downregulate cutaneous immune responses [77].
Moreover, the clearance of tissue-infiltrating macrophages
via LVs has been discussed as an important step in the
resolution of inflammation [78, 79], but also contradicting
data exist on this topic [80].
On the other hand, tissue exit of leukocytes via LVs may
also enhance the inflammatory process. For example, an
activated and expanded lymphatic network is known to
increase the migration of antigen-presenting DCs to dLNs,
what may support the induction of adaptive immunity [16, 69].
This is particularly relevant during organ transplantation,
where studies in humans have revealed a positive correlation
between lymphangiogenesis and transplant rejection [11, 12].
Moreover, in animal models, blocking lymphangiogenesis
was shown to significantly reduce DC migration and graft
rejection [16–19]. However, organ transplantation represents
a special condition, in which lymphatic connectivity with
dLNs need to be formed de novo, and additionally strong allo-
immune responses may be induced. By contrast, in the context
of endogenous tissues with preexisting lymphatic vasculature
and immune connectivity with dLNs, blockade of inflamma-
tion-induced lymphangiogenesis was shown to exacerbate the
inflammatory response, likely due to the enhancement of tis-
sue edema [10, 14, 15].
LV drainage
Increasing evidence suggests that lymphatic drainage is
frequently compromised in the context of chronic inflam-
mation, such as in psoriasis [81, 82] or Morbus Crohn [83,
84]. However, in animal models, both inflammation-
induced enhancement and reduction of lymphatic drainage
has been observed. For example, injection of LPS [27],
reportedly enhanced lymphatic drainage in the skin,
whereas in the diaphragm drainage was reduced in a model
of LPS-induced peritonitis [28], suggesting that the
response of the lymphatic vasculature to an inflammatory
stimulus might not be uniform but organ-specific. How-
ever, such organ-specific differences, have not been studied
in great detail thus far. By contrast, an abundant literature
indicates that the nature of the inflammatory stimulus has a
great impact on lymphatic drainage function. For example,
in the skin, LV drainage reportedly was reduced in the
context of CHS- [85, 86] and UVB-induced [15, 87] skin
inflammation, whereas skin inflammation induced by
transgenic overexpression of interleukin-4 [88] lead to
enhanced lymphatic drainage. Several studies have also
shown that VEGF-A-induced lymphangiogenesis gener-
ated less functional LVs as compared to lymphangiogen-
esis induced by VEGF-C and VEGF-D [15, 71, 87, 89]. In
general, activation of the VEGFR-3 pathway appears to be
an effective way of stimulating productive lymphangio-
genesis and stimulating lymphatic drainage: genetic over-
expression or injection of recombinant VEGF-C was
shown to alleviate UV-B or CHS-induced acute and
chronic skin inflammation [15, 89, 90] as well as chronic
inflammatory arthritis [91], likely by enhancing lymphatic
drainage function. By contrast, inhibition of VEGFR-3
signaling impaired lymphatic growth and exacerbated
inflammation in mouse models of airway inflammation
[10], inflammatory arthritis [14] or chronic skin inflam-
mation [15], likely by promoting tissue edema formation.
Many inflammatory mediators are known to enhance
permeability of BVs, but only few in vivo reports about
effects on LV permeability exist. Nitric oxide (NO) and
VEGF-A were shown to contribute to the leakiness of
dermal LVs in the context of UV-B-induced inflammation
[87, 92]. In vitro, inflammatory mediators such as TNFa,
IL-1, histamine, thrombin and VEGF-C were shown to
decrease the barrier function of LEC monolayers [35, 93,
94]. Moreover, inflammation was also shown to impact the
pumping function of lymphatic collectors. Specifically,
various inflammatory mediators, such as histamine, pros-
taglandins or NO were shown to reduce lymphatic pumping
[95–97], whereas VEGF-C enhanced pumping [98].
Chemokine scavenging
In addition to passively draining tissue fluids and inflam-
matory mediators, LVs have been shown to actively
remove chemokines from inflamed tissues. In particular,
the chemokine scavenging receptor (CSR) D6, which is
expressed by LECs and is upregulated during inflammation
[99], was shown to be important for the resolution of tissue
inflammation [100, 101]. D6 internalizes and degrades
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inflammatory chemokines (i.e. CCL2, 3, 5, 8, 12, 17, 22),
thereby accelerating their elimination from tissues. More-
over, it was recently proposed that D6 functions to ensure
selective presentation of CCL21 on LECs, by suppressing
inflammatory chemokine binding and accumulation. In
inflamed tissues of D6-deficient mice, a massive associa-
tion of myelomonocytic cells around LVs was observed,
leading to obstructed lymphatic drainage and reduced DC
migration to dLNs [100]. Thus far, only the function of D6
in LECs has been analyzed. However, it was recently
reported that another CSR, namely the CXCL11- and
CXCL12-binding CXC chemokine receptor 7 (CXCR7),
was upregulated in inflamed LVs [102]. Thus, it is likely
that besides D6, further CSRs contribute to the inflamma-
tion- and immune-modulating functions of LVs.
Conclusion
Over the last 15 years a lot of progress has been made in
understanding how tissue inflammation alters gene
expression in LECs as well as LV morphology and func-
tion. The emerging view is that the inflammatory response
of the lymphatic endothelium and its impact on LV func-
tionality is very much stimulus-specific and context-
dependent. Depending on the inflammatory stimulus and
the resulting immune response, different pro-/anti-lym-
phangiogenic mediators are produced in the tissue. This
generates a unique milieu, which impacts the inflammatory
response of LECs and the overall nature and extent of
lymphangiogenesis. Such stimulus-specific changes in the
lymphatic vasculature may greatly influence LV function-
ality, such as fluid drainage and leukocyte trafficking.
Recent data also indicate that the same inflammatory
stimulus may have different effects on LV function in
different organs [27, 28]. The latter might be explained by
the fact that clear morphologic [103] and gene expression
[104] differences exist between LVs in different body
parts. However, many of these differences are only now
starting to be unraveled. By contrast, already to date
abundant evidence suggests that the impact of lymphan-
giogenesis on tissue inflammation is very much context-
dependent. Lymphangiogenesis occurring within trans-
planted organs (e.g. cornea [16, 17], heart [18], pancreatic
islands [19] or kidney [11, 12]) has been shown to exac-
erbate tissue inflammation, supposedly by re-establishing
connectivity with the immune system in the dLNs and
hence contributing to the rejection process. On the other
hand, various recent studies reveal that in tissues with a
pre-established LV network (e.g. the skin [89], lung [10] or
joints [14, 91]) productive, in particular VEGF-C-medi-
ated, lymphangiogenesis contributes to the resolution of
inflammation, supposedly by promoting tissue drainage.
Thus, stimulation or inhibition of lymphangiogenesis could
represent an attractive novel therapeutic strategy for
reducing chronic inflammation or transplant rejection,
respectively.
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